Trevena, Inc. (TRVN) EPS Estimated At $-0.16

October 13, 2018 - By Dolores Ford

Trevena, Inc. (NASDAQ:TRVN) Logo

Analysts expect Trevena, Inc. (NASDAQ:TRVN) to report $-0.16 EPS on November, 6.They anticipate $0.11 EPS change or 40.74 % from last quarter’s $-0.27 EPS. After having $-0.13 EPS previously, Trevena, Inc.’s analysts see 23.08 % EPS growth. The stock decreased 7.06% or $0.0669 during the last trading session, reaching $0.8801. About 12.36 million shares traded or 262.77% up from the average. Trevena, Inc. (NASDAQ:TRVN) has declined 40.14% since October 14, 2017 and is downtrending. It has underperformed by 55.76% the S&P500.

Trevena, Inc. (NASDAQ:TRVN) Ratings Coverage

Among 2 analysts covering Trevena (NASDAQ:TRVN), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Trevena had 2 analyst reports since October 10, 2018 according to SRatingsIntel. H.C. Wainwright maintained Trevena, Inc. (NASDAQ:TRVN) rating on Friday, October 12. H.C. Wainwright has “Buy” rating and $3 target. The stock of Trevena, Inc. (NASDAQ:TRVN) earned “Hold” rating by Jefferies on Wednesday, October 10.

Trevena, Inc., a biopharmaceutical company, develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The company has market cap of $66.96 million. The Company’s product candidates include oliceridine injection, a µ-receptor G protein pathway selective modulator, which is in Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in preclinical development for the treatment of migraine; and TRV734, a small molecule G protein biased ligand at the mu-receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. It currently has negative earnings.

More notable recent Trevena, Inc. (NASDAQ:TRVN) news were published by: which released: “Trevena discloses change of Phase 3 endpoints for oliceridine after FDA discussions” on October 11, 2018, also with their article: “Trevena Stock Trading Halted; FDA Advisory Committee to Review Oliceridine for the Treatment of Moderate to Severe …” published on October 11, 2018, published: “Trevena shares halted pending outcome of Ad Com meeting” on October 11, 2018. More interesting news about Trevena, Inc. (NASDAQ:TRVN) were released by: and their article: “AcelRx Shares React Positively To FDA Committee Briefing On Painkiller Candidate Dsuvia” published on October 10, 2018 as well as‘s news article titled: “Trevena down 13% premarket after negative Ad Com vote” with publication date: October 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News